Merck & Co., Inc.

Industry

  • Digital Health
    • Disease Management
  • Pharmaceuticals

Other Names/Subsidiaries

  • Abmaxis
  • Abceutics
  • Acacia Biosciences
  • Acceleron Pharma
  • Adolor Corporation (ADLR)
  • Afferent Pharmaceuticals
  • ArQule
  • Avecia Biologics
  • Aton Pharma (pre Merck & Co)
  • Banyu Pharmaceutical
  • Calporta Therapeutics
  • CAM Biotherapeutics
  • Caraway Therapeutics
  • Ccam Biotherapeutics
  • Cubist Pharmaceuticals
  • Calixa Therapeutics
  • Charles E. Frosst Canada
  • EyeBio
  • GlycoFi
  • Harrisvaccines
  • Harpoon Therapeutics
  • HMR Weight Management Idenix Pharmaceuticals
  • Immune Design Corporation
  • Inspire Pharmaceuticals
  • IOmet Pharma
  • iOnctura
  • Integrated Therapeutics Group
  • IdentiGEN
  • Merck Sharp & Dohme (MSD)
  • Modifi Bio
  • MSD
  • MSD Italia
  • MSD K.K. (Japan)
  • Nobilon International BV
  • NovaCardia
  • OncoEthix SA
  • OncoImmune
  • Organon BioSciences
  • Optimer Pharmaceuticals
  • Oncoethix
  • Pandion Therapeutics
  • Peloton Therapeutics
  • ProVantage Health Services
  • Prometheus Biosciences
  • Rigontec
  • Rosetta Inpharmatics
  • Schering-Plough
  • SIBIA Neurosciences
  • SmartCells
  • Tilos Therapeutics
  • Trius Therapeutics
  • Themis Biosciences
  • Tilos Therapeutics
  • Vaki
  • Vallee S.A
  • VelosBio
  • Viralytics
See more in Biomedtracker

Latest on Merck & Co., Inc.

Scrip

Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label

 
• By Joseph Haas

Merck & Co. presented full data from a Phase III trial testing Keytruda (pembrolizumab) as perioperative treatment in stage III or IVA resected, locally advanced head and neck squamous cell carcin

Scrip

Merck & Co. CMO Eliav Barr Assures On Pipeline As Keytruda LOE Looms Large

 
• By Jessica Merrill

Investors are acutely focused on the loss of exclusivity (LOE) of Merck & Co.’s mega-blockbuster Keytruda (pembrolizumab) in 2028, but head of global clinical development and chief medical officer

Scrip

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

 
• By Dexter Jie Yan

Akeso apparently disagreed with investors’ reactions after the Chinese biotech on 25 April provided an early release of preliminary overall survival (OS) data from an interim analysis of a high-stakes

Scrip

AbbVie Increases US Manufacturing, But Says It’s Not Because Of Tariffs

 
• By Joseph Haas

During its first quarter sales and earnings call on 25 April, AbbVie CEO Robert Michael expressed confidence that the company can weather the current tariffs introduced by the Trump Administration as